What is the current Indapamide market size?

The Indapamide market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Indapamide market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driving the future outlook.

What are the key drivers of the Indapamide market?

Increasing hypertension prevalence and rising demand for antihypertensive drugs are key drivers of the Indapamide market.

What challenges does the Indapamide market face?

The market faces challenges such as patent expirations and intense competition from generic drugs.

Which regions are the leaders in the Indapamide market?

North America and Europe are the regional leaders in the Indapamide market, driven by high healthcare expenditure.

Who are the top companies in the Indapamide market?

Top companies include Servier Laboratories, Mylan, and Teva Pharmaceutical, which dominate the market share.

What future opportunities exist in the Indapamide market?

Emerging markets and increasing demand for combination therapies present future opportunities for growth and expansion.

How does technology impact the Indapamide market?

Advances in drug delivery technologies and digital health platforms are expected to impact the Indapamide market positively.

What is the regulatory landscape of the Indapamide market?

The market is regulated by stringent FDA and EMA guidelines, ensuring safety and efficacy of Indapamide products.

Indapamide Market Growth Drivers & Forecast 2033

Indapamide by Application (Diuretic, Hypertension Treatment, Other), by Types (1.25 mg Indapamide Tablets, 2.5 mg Indapamide Tablets), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Indapamide Market Size | CAGR 5.2 Forecast 2033

Indapamide Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Indapamide Market Overview

The Indapamide market refers to the global industry involved in the development, manufacturing, and distribution of Indapamide, a medication used to treat hypertension and edema. As a crucial component of the pharmaceutical industry, the Indapamide market size is expected to experience significant growth, driven by an increasing prevalence of cardiovascular diseases and an aging population, thereby influencing the growth outlook and market forecast. The industry expansion is anticipated to be substantial, with the global Indapamide market valued at approximately $1.3 billion in 2025. The market is projected to grow at a CAGR of around 4.5% during the forecast period, driven by macro drivers such as advancements in medical technology, changing lifestyles, and rising healthcare expenditure.

Loading chart…

Key forces shaping the Indapamide industry include technology shifts towards more efficient and cost-effective manufacturing processes, regulatory changes aimed at improving drug safety and efficacy, and consumer behavior driven by increasing health awareness and demand for convenient treatments. The largest region for the Indapamide market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by rapid urbanization, expanding healthcare infrastructure, and growing demand for pharmaceuticals. As the Indapamide market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends, challenges, and opportunities to remain competitive and drive industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	7.20 million
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Servier; Cigna; ANI Pharma; Mylan; Teva; Shandong Yinfeida Pharmaceutical; Taj Pharmaceuticals; Supra Chemicals; Glenmark Pharmaceuticals; Suzhou Lixinpharm; Lisheng Pharma; Apeloa Kangyu
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Indapamide market is poised for significant growth, driven by increasing demand for effective hypertension treatments. The Indapamide market size is expected to expand substantially, with a growth forecast that underscores the potential for innovative therapies to capture market share.

Growth Drivers2 items

Rising prevalence of hypertension and related cardiovascular diseases is driving demand for Indapamide, a thiazide-like diuretic, with its unique pharmacological profile offering benefits in terms of efficacy and safety

Advancements in drug formulation technology have improved the bioavailability and patient compliance of Indapamide, further boosting its adoption and contributing to the growth forecast of the Indapamide market

Restraints2 items

The Indapamide market faces challenges from generic competition, which can erode the market share of branded products and impact the overall Indapamide market size

Stringent regulatory requirements and varying reimbursement policies across different regions can limit the uptake of Indapamide, affecting the growth forecast and market dynamics

Opportunities2 items

Emerging markets present significant opportunities for the Indapamide market, driven by increasing healthcare spending, growing awareness of hypertension, and improving access to healthcare services

The development of combination therapies that include Indapamide offers opportunities for pharmaceutical companies to differentiate their products and capture a larger share of the Indapamide market

Challenges2 items

The Indapamide market must navigate the challenges of patent expirations, which can lead to increased generic competition and downward pressure on prices, ultimately affecting the Indapamide market size and growth forecast

Pharmaceutical companies must balance the need for competitive pricing with the requirement to invest in research and development to stay ahead in the Indapamide market, ensuring long-term sustainability and growth

Market Segmentation

Loading chart…

The Indapamide segmentation by application is a crucial aspect of understanding the market dynamics. The Indapamide market can be segmented into various applications, including hypertension treatment, edema treatment, and heart failure treatment. Each application contributes to the overall Indapamide market size, with hypertension treatment being the largest contributor. The application segment is significant as it helps in identifying the target audience and tailoring marketing strategies to cater to their specific needs.

The Indapamide market can be further segmented by types, which include Indapamide SR and Indapamide PR. Indapamide SR is a sustained-release formulation, while Indapamide PR is a prolonged-release formulation. These types of Indapamide have different pharmacokinetic profiles and are used to treat various conditions. Understanding the types of Indapamide is essential for market taxonomy and helps in identifying the most effective treatment options for patients. The types segment also plays a critical role in determining the market size and share of each type of Indapamide.

Indapamide Segmentation Breakdown7 items

Application

Diuretic

Hypertension Treatment

Other

Types

1.25 mg Indapamide Tablets

2.5 mg Indapamide Tablets

Regional Insights

Loading chart…

The Indapamide market growth is expected to vary across regions, with the largest share held by North America, accounting for approximately 35% of the global market. The fastest-growing region is anticipated to be the Asia Pacific, driven by increasing adoption of Indapamide in the treatment of hypertension and related cardiovascular diseases.

Key drivers for each region include: for North America, policies supporting the use of generic medications, significant investments in healthcare infrastructure, and a mature ecosystem. In Europe, factors such as high demographics of aging population, strict regulations, and advanced infrastructure contribute to the growth. The Asia Pacific region is driven by rapid urbanization, increasing adoption of modern healthcare practices, and large-scale investments in pharmaceutical research. Latin America's growth is influenced by expanding policies for public health, improving demographics, and rising infrastructure development. The Middle East & Africa region is seeing growth due to government investments in healthcare, a growing ecosystem for pharmaceuticals, and increasing adoption of advanced medical treatments.

The regional forecast indicates that the Asia Pacific will experience the highest growth rate, driven by the aforementioned factors. Understanding these regional dynamics is crucial for stakeholders to navigate the Indapamide market effectively and capitalize on emerging opportunities.

Competitive Landscape

The Indapamide market is moderately consolidated, with a mix of global players and local/regional companies. The Indapamide competitive landscape is driven by key competitive levers such as pricing, distribution, and product innovation. Global players focus on certifications and regulatory approvals to maintain their market position, while local companies concentrate on regional expansion and partnerships to increase their market share.

Companies in the Indapamide market employ various strategies to differentiate themselves, including M&A, partnerships, and product launches. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must focus on technology, service model, and channel strength. The following companies have adopted distinct strategies:

Servier: regional expansion

Cigna: premium pricing

ANI Pharma: innovation pipeline

Mylan: OEM tie-ups

Teva: local manufacturing

Shandong Yinfeida Pharmaceutical: vertical integration

Key Indapamide Companies12 items

Servier

Cigna

ANI Pharma

Mylan

Teva

Shandong Yinfeida Pharmaceutical

Taj Pharmaceuticals

Supra Chemicals

Glenmark Pharmaceuticals

Suzhou Lixinpharm

Lisheng Pharma

Apeloa Kangyu

Market Ecosystem

The Indapamide ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream channels and end users. This ecosystem can be broadly segmented into three key stages: upstream, where raw materials and components are sourced; midstream, where manufacturing and integration occur; and downstream, where products are distributed and consumed. Understanding the Indapamide ecosystem requires a thorough value chain analysis, as it is here that value is created and captured.

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce Indapamide tablets and formulations

Technology providers — develop and license formulation technologies

Distributors / channel partners — manage logistics and supply chain operations

Service providers / after-sales — offer patient support and education services

End users / buyers — prescribe and consume Indapamide products

Regulators/standards bodies — set and enforce quality and safety standards

In the Indapamide ecosystem, control points are primarily held by regulators and manufacturers, as they influence adoption through approvals, quality standards, and formulation innovations. Dependency risks arise from input constraints, such as raw material availability, and regulatory approvals. Switching costs are relatively low for end users, but partnerships between manufacturers and distributors can create interoperability requirements. The ecosystem's structure and dynamics can differ significantly by region, with varying regulatory environments and market conditions influencing the flow of value and the relationships between participants.

Recent Industry Insights

The Indapamide industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have focused on enhancing research and development capabilities, leading to the introduction of new formulations and combinations. Notably, there have been strategic mergers and acquisitions aimed at expanding product portfolios and strengthening market presence. Furthermore, innovations in drug delivery technologies have resulted in the launch of improved Indapamide products, offering better patient outcomes. Regulatory changes have also played a crucial role, with updated guidelines influencing the manufacturing and approval processes. Shifts in consumer preferences towards more convenient and effective treatments have driven the demand for advanced Indapamide formulations. Additionally, several companies have secured funding rounds to support the development of novel Indapamide-based therapies, underscoring the industry's potential for growth.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Indapamide market outlook. The market attractiveness is moderate, driven by the increasing prevalence of hypertension and the growing demand for antihypertensive medications. The competitive intensity is high, with several key players operating in the market. The long-term outlook is positive, with opportunities for growth in emerging markets and the development of new formulations.

The innovation landscape is evolving, with a focus on developing sustained-release formulations and combination therapies. The demand–supply balance is currently stable, but may be affected by factors such as regulatory changes and supply chain disruptions. Key risk factors include intense competition, patent expirations, and regulatory challenges. Overall, the Indapamide market outlook is favorable, with opportunities for growth and innovation in the coming years.

12 items

1. Executive Summary

2. Indapamide Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Indapamide Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Indapamide Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Indapamide Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Indapamide Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Indapamide Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Indapamide Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Indapamide Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Indapamide Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Indapamide Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Indapamide Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Indapamide Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Indapamide Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Indapamide Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Indapamide Market Competition by Key Manufacturers

9.1. Global Indapamide Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Indapamide: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Servier

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Cigna

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. ANI Pharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Mylan

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Teva

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Shandong Yinfeida Pharmaceutical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Taj Pharmaceuticals

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Supra Chemicals

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Glenmark Pharmaceuticals

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Suzhou Lixinpharm

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Lisheng Pharma

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Apeloa Kangyu

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Indapamide Market

Figure 4: Global Indapamide Market: Drivers

Figure 5: Global Indapamide Market: Challenges

Figure 6: Global Indapamide Market: Trends

Figure 7: Global Indapamide Market: Opportunity

Figure 8: Global Indapamide Market: Restraint

Figure 9: Global Indapamide Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Indapamide Market Value (USD Million) By Region

Figure 19: Global Indapamide Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Indapamide Market Value (USD Million) By Region

Figure 27: Global Indapamide Market Share (%) By: Regions (2032)

Figure 28: Global Indapamide Market Volume (K) By Region

Figure 29: Global Indapamide Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Indapamide Market Value (USD Million) By Region

Figure 37: Global Indapamide Market Share (%) By: Regions (2032)

Figure 38: Global Indapamide Market Volume (K) By Region

Figure 39: Global Indapamide Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Indapamide Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Indapamide Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Indapamide Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Indapamide Market Value (USD Million) By Region

Table 14: Global Indapamide Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Indapamide Market Volume (K) By Region

Table 31: Global Indapamide Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Indapamide Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Indapamide Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Indapamide Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Servier Basic Information And Sales Area

Table 52: Servier. Products Portfolio

Table 53: Cigna Basic Information And Sales Area

Table 54: Cigna. Products Portfolio

Table 55: ANI Pharma Basic Information And Sales Area

Table 56: ANI Pharma. Products Portfolio

Table 57: Mylan Basic Information And Sales Area

Table 58: Mylan. Products Portfolio

Table 59: Teva Basic Information And Sales Area

Table 60: Teva. Products Portfolio

Table 61: Shandong Yinfeida Pharmaceutical Basic Information And Sales Area

Table 62: Shandong Yinfeida Pharmaceutical. Products Portfolio

Table 63: Taj Pharmaceuticals Basic Information And Sales Area

Table 64: Taj Pharmaceuticals. Products Portfolio

Table 65: Supra Chemicals Basic Information And Sales Area

Table 66: Supra Chemicals. Products Portfolio

Table 67: Glenmark Pharmaceuticals Basic Information And Sales Area

Table 68: Glenmark Pharmaceuticals. Products Portfolio

Table 69: Suzhou Lixinpharm Basic Information And Sales Area

Table 70: Suzhou Lixinpharm. Products Portfolio

Table 71: Lisheng Pharma Basic Information And Sales Area

Table 72: Lisheng Pharma. Products Portfolio

Table 73: Apeloa Kangyu Basic Information And Sales Area

Table 74: Apeloa Kangyu. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Market Volume (K) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Types

Table 82: Global Market Share (%) By Types (2032)

Table 83: Global Indapamide Market Value (USD Million) By Region

Table 84: Global Indapamide Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Application

Table 87: North America Market Value (USD Million) (2025-2032) By Types

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Types

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Types

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 100: Global Indapamide Market Volume (K) By Region

Table 101: Global Indapamide Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Application

Table 104: North America Market Volume (K) (2025-2032) By Types

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Types

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Types

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Indapamide Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	7.20 million
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Servier; Cigna; ANI Pharma; Mylan; Teva; Shandong Yinfeida Pharmaceutical; Taj Pharmaceuticals; Supra Chemicals; Glenmark Pharmaceuticals; Suzhou Lixinpharm; Lisheng Pharma; Apeloa Kangyu
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options